阿托伐他汀钙联合苯磺酸左旋氨氯地平治疗高血压合并冠心病的临床疗效

Clinical efficacy of Atorvastatin calcium combined with levamlodipine besylate in the treatment of hypertension complicated with coronary heart disease

目的探讨阿托伐他汀钙与苯磺酸左旋氨氯地平联合应用于高血压合并冠心病治疗中的临床疗效。方法将2016年1月~2017年12月我院收治的90例高血压合并冠心病患者作为研究对象,将其按照自主意愿选择阿托伐他汀钙联合苯磺酸左旋氨氯地平治疗的患者作为观察组(n=48),选择单一苯磺酸左旋氨氯地平治疗的患者作为对照组(n=42),分别对比两组患者的临床疗效、血压水平、血脂水平及心绞痛症状改善情况。结果观察组患者的临床总有效率95.8%明显高于对照组的81%(χ~2=14.271,P=0.001);治疗后观察组患者的收缩压与舒张压水平均明显低于对照组;治疗后观察组患者的TC、TG、LDL-C水平均明显低于对照组;观察组患者的心绞痛症状改善总有效率(89.6%)明显高于对照组的59.5%(χ~2=14.365,P=0.001),差异均有统计学意义(P<0.05)。结论阿托伐他汀钙与苯磺酸左旋氨氯地平联合治疗高血压合并冠心病能进一步提升临床疗效,提高血压、血脂的控制效果,促进患者心绞痛症状的改善,具有较高的临床应用价值。

Objective To investigate the clinical efficacy of atorvastatin calcium combined with levamlodipine besylatein the treatment of hypertension complicated with coronary heart disease. Methods 90 patients with hypertension complicated with coronary heart disease who were admitted to our hospital from January 2016 to December 2017 were selected as the study subjects. Patients who were treated with atorvastatin calcium combined with levamlodipine besylateaccording to their own willingness were selected as the observation group （n=48）, and patients treated with levamlodipinebesylate alone were selected as the control group （n=42）. The clinical efficacy, blood pressure level, blood lipid leveland improvement of angina symptoms were compared between the two groups. Results The clinical total effective ratein the observation group was 95.8%, which was significantly higher than that of 81% in the control group（字2=14.271, P=0.001）; the systolic blood pressure and diastolic blood pressure in the observation group after treatment were significantly lower than those in the control group. After treatment, the TC, TG , and LDL-C levels in the observation groupwere significantly lower than those in the control group; the total effective rate of improvement of angina symptoms（89.6%） in the observation group was significantly higher than that of（59.5%） in the control group（字2=14.365, P=0.001）.All the differences were statistically significant （P〈0.05）. Conclusion The combination of atorvastatin calcium and levamlodipine besylate in the treatment of hypertension complicated with coronary heart disease can further improve theclinical efficacy, improve the control effect of blood pressure and blood lipids, promote the improvement of angina pectoris symptoms, and has a high clinical application value.